-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1862 Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Program: Oral and Poster Abstracts
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical trials, Lymphoid Leukemias, CLL, Lymphomas, Clinical Research, Diseases, Aggressive lymphoma, Lymphoid Malignancies
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Tamar Tadmor, MD1,2*, Ohad Benjamini, MD3,4*, Neta Goldschmidt5,6*, Natalia Kreiniz, MD7,8*, Osnat Bairey9,10*, Reut Harel, MD11*, Nadav Sarid12,13*, Tsofia Levi, MD14*, Ofir Wolach, MD15,16* and Yair Herishanu, MD17,18*

1Technion, Ruth and Bruce Rappaport Faculty of Medicine,, Haifa,, Israel
2Hematology Unit, Bnai Zion Medical Center, Haifa, Israel
3Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
4Hematology and BMT, Sheba Medical Center–Tel HaShomer, Ramat Gan, Israel
5Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
6Department of Hematology, Hadassah Medical Center, Jerusalem, Israel
7Hematology, Bnai Zion Medical Center, Haifa, Israel
8Ruth and Bruce Rappaport Faculty of Medicine, Technion,, Haifa, Israel
9Davidoff Cancer Center, Rabin Medical Center,, Petach Tikva, ISR
10School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University,, Tel Aviv,, Israel
11Department of Hematology, Emek Medical Center, Afula, Ein-Dor, Israel
12Faculty of Medicine, Tel Aviv University, Tel Aviv, Tel Aviv, Israel
13Department of Hematology, Edith Wolfson Medical Center, Holon, Holon, Israel
14Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
15Tel Aviv University, The Faculty of Medicine & Health Sciences, Tel Aviv, Israel
16Rabin Medical Center, Petah Tikva, Israel
17School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv,, Israel
18Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

Background: Richter's syndrome (RS) is a rare histologic transformation of chronic lymphocytic leukemia (CLL), most commonly to diffuse large B-cell lymphoma (DLBCL). It is characterized by an aggressive clinical course and dismal prognosis. Treatment is usually based on regimens traditionally used for de novo DLBCL like R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-DA-EPOCH (rituximab and dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). The outcomes with chemo-immunotherapy in RS are poor, achieving a complete response rate (CRR) of about 20% to 30% of patients and median progression-free survival (PFS) and overall survival (OS) in the range of 6 and 12 months, respectively.

Methods: This is a phase 2, open-label, non-randomized, single-arm, multi-center study aimed to assess the efficacy and safety of 12-month fixed duration obinutuzumab, ibrutinib, and venetoclax (GIVe) in patients with DLBCL-type RS (NCT04939363). Obinutuzumab was administered IV for 6 cycles, starting with 100 mg on day 1 and 900 mg on day 2, 1000 mg on day 8 and on day 15 of cycle 1, and subsequently 1000 mg on day 1 of cycles 2 through 6. ibrutinib 560 mg daily was administered orally from day 1 of cycles 1 through 12. The daily oral venetoclax regimen was initiated on day 11 of cycle 1, starting with an accelerated ramp-up, thereafter continuing at 400 mg daily until completion of cycle 12. The primary endpoint was investigator-assessed 6-month overall metabolic response rate per Lugano 2014 criteria. Other key secondary endpoints included complete metabolic response (CMR) rate, PFS, OS, and safety.

Results: From August 2021 until the data cut-off on July 7, 2024, a total of 12 patients with RS were enrolled, with a median age of 78.0 years (range, 62-87), 8 (67%) were males, 8 (67%) were treatment-naïve, 4 (37%) had relapsed/refractory disease, 5 (42%) had extra-nodal disease, 8 (67%) had elevated LDH, and 9 (75%) were double or triple-expressors (Table 1). Among the 10 patients who were evaluable for response, the 3-month and 6-month OMR rates were 70.0% (7/10) and 37.5% (3/8), respectively, and the 3-month and 6-month CMR rates were 40.0% (4/10) and 25% (2/8), respectively. During a median follow-up of 23 months (range, 1-32), 6/12 (50 %) progressed and 10/12 (83.3 %) died. Median PFS was 4.4 months (95% CI, 1-11.9) and median OS was 7.8 months (95% CI: 1-32). Causes of death included RS (n=3), intractable diarrhea (n=2), infections (n=2; one case of sepsis and one case of Covid-19 during the next-line therapy with bendamustine plus rituximab), neurological deterioration (n=2), and acute myeloid leukemia (n=1). Most common related treatment-emergent adverse events (TEAEs) of all grades were neutropenia 40%, thrombocytopenia 50%, diarrhea 40%, and skin rash 50%, 2 patients developed Covid-19 and recovered during the treatment period of the study. None of the patients developed tumor lysis syndrome or atrial fibrillation.

Conclusions: In elderly patients with RS, 12-month fixed duration obinutuzumab, ibrutinib, and venetoclax treatment achieved high 3-month metabolic responses. Despite the early encouraging response, the duration of response, PFS, and OS were short. This three-drug regimen appears to be less well tolerated in elderly patients with RS

Disclosures: Tadmor: Janssen, roche, abbvie, astra, takeda, novartis, beigene, medison: Consultancy, Research Funding. Goldschmidt: Abbvie, Janssen, AstraZeneca: Consultancy. Sarid: Abbvie, Janssen, AstraZeneca: Consultancy, Honoraria. Wolach: Pfizer: Honoraria; Teva: Honoraria; Amgen: Honoraria; Medison: Honoraria; Abbvie, Janssen,: Consultancy, Honoraria, Research Funding; Astellas: Honoraria. Herishanu: Abbvie, Janssen, AstraZeneca: Consultancy, Honoraria.

*signifies non-member of ASH